Safety and efficacy of Tofacitinib, an oral Janus Kinase inhibitor, up to 36 Months in patients with active Psoriatic Arthritis: data from the third interim analysis of OPAL balance, an Open-Label, long-term extension study - Nash, P; Coates, L; Kivitz, A; Mease, P; Gladman, D; Covarrubias-Cobos, J; Fleishaker, D; Wang, C; Kudlacz, E; Menon, S; Fallon, L; Hendrikx, T; et al. (Wiley, 2018)